



Q1 2015 results

Shire delivers strong revenue growth and cash generation; 20% increase in Non GAAP earnings per ADS

April 30, 2015

Flemming Orm
CEO

Jeff Poulton
CFO

“SAFE HARBOR” statement under the Private Securities Litigation Reform Act of 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's financial condition may be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

- Shire's products may not be a commercial success;
- product sales from ADDERALL XR[®] and INTUNIV[®] are subject to generic competition;
- the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for Shire's products may affect future revenues, financial condition and results of operations;
- Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers for other products and to provide goods and services. Some of the Shire's products or ingredients are only available from a single source for manufacture. Any disruption to the supply chain for any of the Shire's products may result in Shire being unable to manufacture, market or develop a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
- the manufacture of Shire's products is subject to extensive oversight by various regulatory agencies. Regulatory approvals and changes associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increased operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
- Shire has a portfolio of products in various stages of research and development. The successful development of these products is uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
- the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution by such customers can adversely affect Shire's revenues, financial conditions or results of operations;
- investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
- Shire faces intense competition for highly qualified personnel from other companies and organizations. Shire is undergoing a reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect Shire's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;
- failure to achieve Shire's strategic objectives with respect to the acquisition of NPS Pharmaceuticals, Inc. may adversely affect Shire's financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire's filings with the US Securities and Exchange Commission, including its recent Annual Report on Form 10-K.

Q1 2015: On track to become a leading global biotechnology company

GROWTH

- ✓ Strong top and bottom line growth and cash generation
- ✓ Close of NPS acquisition
- ✓ Launch of NATPARA in HPT
- ✓ Approval and launch of VYVANSE in BED

INNOVATION

- ✓ FDA acceptance of NDA for li signs and symptoms of Dry E with Priority review
- ✓ Clear regulatory path forward in adult ADHD
- ✓ Acquisition of Meritage expanding pipeline with late stage assets in eosinophilic esophagitis

EFFICIENCY


- ✓ US site consolidation well underway
- ✓ NPS integration progressing as planned

PEOPLE


- ✓ Jeff Poulton appointed as Chief Officer

Delivering strong sales and Non GAAP EBITDA growth

Product Sales



Non GAAP EBITDA⁽¹⁾⁽³⁾



Strong product sales and Non GAAP EBITDA⁽¹⁾⁽³⁾ growth despite generic competition to INTUNIV and FX headwinds

Growth across the product portfolio



VYVANSE sales \$417M; +20%⁽¹⁾

- US growth driven by volume gains – especially post launch of BED - and price
- International growth continues to benefit from gains in established markets



LIALDA sales \$148M; +17%⁽¹⁾

- US prescription growth of 12% (in a flat market) drove a 4% increase in market share versus prior year
- Sales growth aided by a price increase slightly offset by higher destocking; significant destocking versus Q4 2014



CINRYZE sales \$148M; +28%⁽²⁾

- Strong increase in patients and utilization
- Accelerated growth as product has benefited from Shire's Rare Disease expertise



FIRAZYR sales \$92M; +26%⁽¹⁾

- Increased number of patients and price
- Upward momentum continues ~3 years post US launch
- CINRYZE complementarity has accelerated gains



GATTEX sales \$15M; +44%⁽³⁾

- Gattex is included in reported sales from 21 February 2015
- Integration progressing according to plan
- Second consecutive quarter of positive growth for completed patient referral a precursor of therapy initiation

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.